OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Impact of MASLD and MetALD on clinical outcomes: A meta‐analysis of preliminary evidence
Stefano Ciardullo, Alessandro Mantovani, Mario Luca Morieri, et al.
Liver International (2024) Vol. 44, Iss. 8, pp. 1762-1767
Closed Access | Times Cited: 15
Stefano Ciardullo, Alessandro Mantovani, Mario Luca Morieri, et al.
Liver International (2024) Vol. 44, Iss. 8, pp. 1762-1767
Closed Access | Times Cited: 15
Showing 15 citing articles:
Editorial: Lipidomics in MASLD and MetALD
Rajalakshmi Govalan, Vincent Chen
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Rajalakshmi Govalan, Vincent Chen
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
Haixiang Zheng, Leonardo A. Sechi, Eliano Pio Navarese, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Haixiang Zheng, Leonardo A. Sechi, Eliano Pio Navarese, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Steatotic Liver Disease Prevalence in China: A Population‐Based Study and Meta‐Analysis of 17.4 Million Individuals
Zhenqiu Liu, Jiayi Huang, Luojia Dai, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access
Zhenqiu Liu, Jiayi Huang, Luojia Dai, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access
From NAFLD to MASLD: what does it mean?
Lampros Chrysavgis, Εvangelos Cholongitas
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 6, pp. 217-221
Closed Access | Times Cited: 4
Lampros Chrysavgis, Εvangelos Cholongitas
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 6, pp. 217-221
Closed Access | Times Cited: 4
Liver and Atherosclerotic Risk of Alcohol Consumption in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
Shaowen Wang, C. H. Wang, Yu‐Ming Cheng, et al.
Atherosclerosis (2025) Vol. 403, pp. 119161-119161
Closed Access
Shaowen Wang, C. H. Wang, Yu‐Ming Cheng, et al.
Atherosclerosis (2025) Vol. 403, pp. 119161-119161
Closed Access
From NAFLD to MASLD: transforming steatotic liver disease diagnosis and management
Paula Iruzubieta, Carolina Jiménez-González, Joaquín Cabezas, et al.
Metabolism and Target Organ Damage (2025) Vol. 5, Iss. 1
Open Access
Paula Iruzubieta, Carolina Jiménez-González, Joaquín Cabezas, et al.
Metabolism and Target Organ Damage (2025) Vol. 5, Iss. 1
Open Access
Modifiable Risk Factors for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis
Shiyu Xiao, Ya Liu, Xiliang Fu, et al.
The American Journal of Medicine (2024) Vol. 137, Iss. 11, pp. 1072-1081.e32
Closed Access | Times Cited: 3
Shiyu Xiao, Ya Liu, Xiliang Fu, et al.
The American Journal of Medicine (2024) Vol. 137, Iss. 11, pp. 1072-1081.e32
Closed Access | Times Cited: 3
Is liver fibrosis more advanced in MetALD than in MASLD?
Hideki Fujii, Yoshihiro Kamada, Akihiro Tokushige, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 2
Hideki Fujii, Yoshihiro Kamada, Akihiro Tokushige, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 2
From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction
Stefano Ciardullo, Gianluca Perseghin
Metabolism and Target Organ Damage (2024)
Open Access | Times Cited: 2
Stefano Ciardullo, Gianluca Perseghin
Metabolism and Target Organ Damage (2024)
Open Access | Times Cited: 2
Impact of the MetALD terminology on the prevalence of alcohol‐related fatty liver disease in US adults (2017–2020)
Yasser Fouad, Takumi Kawaguchi, Yusuf Yılmaz
Liver International (2024) Vol. 44, Iss. 11, pp. 3112-3113
Closed Access
Yasser Fouad, Takumi Kawaguchi, Yusuf Yılmaz
Liver International (2024) Vol. 44, Iss. 11, pp. 3112-3113
Closed Access
Authors' response to Guo, Wei et al.
Stefano Ciardullo, Gianluca Perseghin
Liver International (2024)
Closed Access
Stefano Ciardullo, Gianluca Perseghin
Liver International (2024)
Closed Access
Letter regarding ‘Impact of MASLD and MetALD on clinical outcomes: A meta‐analysis of preliminary evidence’
Menglu Guo, Xiaoyuan Wei, Yu Min
Liver International (2024)
Closed Access
Menglu Guo, Xiaoyuan Wei, Yu Min
Liver International (2024)
Closed Access
Prevalence, characteristics and outcomes of patients with metabolic and alcohol related/associated liver disease: a systematic review and meta-analysis
Maria Tampaki, Emmanuel Tsochatzis, Vasileios Lekakis, et al.
Metabolism (2024) Vol. 163, pp. 156101-156101
Closed Access
Maria Tampaki, Emmanuel Tsochatzis, Vasileios Lekakis, et al.
Metabolism (2024) Vol. 163, pp. 156101-156101
Closed Access
Bubu A. Banini, Sandeepkumar Chauhan, Ayesha Amatya, et al.
Alcohol Clinical and Experimental Research (2024)
Open Access
Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response
Camilo Julio Llamoza-Torres, María Fuentes-Pardo, Bruno Ramos‐Molina
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 4
Open Access
Camilo Julio Llamoza-Torres, María Fuentes-Pardo, Bruno Ramos‐Molina
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 4
Open Access
